bit.bio discovery
- Company typePrivate
- Founded2020
- HeadquartersVienna, Austria
- Headcount11–50
- GTM typeB2B
- OfferingServices
bit.bio discovery firmographics
Firmographics- Name
- bit.bio discovery
- Legal name
- Bit Bio Discovery GmbH
- Website
- https://bitbiodiscovery.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
bit.bio discovery industry classification
Industry- Product category
- Functional Genomics Screening Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
Keywords
Where bit.bio discovery is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
bit.bio discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CRISPR Screening Services: Fee-for-service model providing functional genomic screening using customer-provided or company's ioCells™ iPSC-derived models. Services include CRISPR knockout, knockdown, and activation screens with custom readouts including transcriptomics, flow cytometry, microscopy, and bioinformatic analysis.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom service engagements based on customer requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
bit.bio discovery product offering
Product offeringCore offering
bit.bio discovery provides iPSC-derived cell models (ioWild Type Cells and ioDisease Model Cells) and custom cell engineering services for drug discovery research. The company runs CRISPR functional genomics screening services, including knockout, activation, and interference screens, on customer-supplied or proprietary iPSC-derived cells to support target identification, validation, pathway analysis, and disease modelling for pharmaceutical and biotechnology clients.
Product overview
bit.bio discovery is a functional genomics screening platform that combines iPSC-derived cell models with CRISPR technologies. The core offering includes ioWild Type Cells™ (defined iPSC-derived cells from healthy donors including ioGlutamatergic Neurons™, ioGABAergic Neurons™, ioMicroglia™, ioSensory Neurons™, ioOligodendrocyte-like cells™, and ioSkeletal Myocytes™) and ioDisease Model Cells™ (disease-relevant mutant cell lines paired with isogenic wild-type controls). The platform is powered by opti-ox™ precision reprogramming technology and CROP-Seq (CRISPR droplet sequencing) combining pooled CRISPR screening with single-cell RNA sequencing. Services include CRISPR knockout, activation, and interference screens for drug target identification, validation, mechanism of action studies, and disease modelling. Customers can use their own iPSC-derived cell models or select from the ready-to-screen ioCells™ portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- ioCells™: Ready-to-screen iPSC-derived cell models powered by opti-ox™ precision cellular reprogramming technology.
- ioWild Type Cells™
- ioDisease Model Cells™
- opti-ox™
Products and services
- ioWild Type Cells Defined and functional iPSC-derived cells from a healthy donor background that are ready for CRISPR screening, including glutamatergic neurons, GABAergic neurons, microglia, sensory neurons, oligodendrocyte-like cells, and skeletal myocytes. Used by pharmaceutical and biotechnology researchers as physiologically relevant human cell models.
- ioDisease Model Cells iPSC-derived cells engineered to contain disease-relevant mutations. Each ioDisease Model Cell can be paired with a genetically matched ioWild Type Cell, forming an isogenic pair for CRISPR screening. Disease indications include Huntington's Disease, FTD and ALS, Parkinson's and Gaucher Disease, Fragile X Syndrome, and Duchenne Muscular Dystrophy.
- CRISPR Screening Service Functional genomic screening service using CRISPR knockout, CRISPR activation (CRISPRa), and CRISPR interference (CRISPRi) technologies applied to iPSC-derived cell models. Supports drug target identification, validation, pathway analysis, and disease modelling, with custom readouts including transcriptomics, flow cytometry, microscopy, and bioinformatic analysis. Customers can use their own iPSC-derived models or select from ready-to-screen ioCells.
- Custom Cell Engineering Service Custom iPSC-derived cell model generation with precise introduction of disease-associated mutations or gene modifications tailored to customer research objectives. Supports bespoke cell engineering projects beyond the standard ioWild Type and ioDisease Model Cell portfolio.
Quantifiable outcome
- Functional genomic screens can be performed at large scale with unbiased, conclusive data output
Companies that use bit.bio discovery
Customer profileSegments2 records
Ideal customer profiles2 records
bit.bio discovery technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
bit.bio discovery partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Myllia BiotechnologycoreJoint venture partner and parent company. bit.bio discovery is a joint venture between Vienna-based Myllia Biotechnology and Cambridge-based bit.bio. Myllia Biotechnology (formerly Aelian Biotechnology) focuses on single-cell CRISPR screens and was co-founded by Tilmann Bürckstümmer in 2018. Thomas Moser served as founder and CEO of Myllia Biotechnology since 2018.
- bit.biocoreJoint venture partner and parent company. Cambridge-based bit.bio is a biotechnology company specializing in precision cell programming. The joint venture combines Myllia's expertise in CRISPR screening with bit.bio's opti-ox™ technology for precision cellular reprogramming.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
bit.bio discovery competitors and assessment
Company assessmentBroad incumbents
- Horizon Discovery (Revvity): Now part of Revvity, Horizon Discovery offers gene-edited cell lines, CRISPR screening tools, and cell-based screening services to pharma. It is the most direct incumbent competitor to bit.bio discovery's CRISPR screening offering and shares leadership alumni (Bürckstümmer, Moser both worked there).
- Evotec: Global CRO offering iPSC-based disease modeling, CRISPR screening, and drug discovery services to pharma. A scaled incumbent with overlapping capabilities in functional genomics and human disease models, and significantly broader service portfolio.
- Charles River Laboratories: Large CRO offering cell biology, CRISPR, and iPSC-derived services across drug discovery. Provides an established global alternative for pharma buyers evaluating functional genomics partners, competing at the enterprise end of the market.
- New England Biolabs: Major life sciences reagent and tools supplier with growing CRISPR and cell-based assay offerings. A broad incumbent in the genomic tools category relevant to bit.bio discovery's customer base.
Emerging players
- bit.bio: Cambridge-based parent JV partner that develops iPSC-derived human cells using opti-ox™ reprogramming for research, drug discovery, and cell therapy. Provides the underlying cell reprogramming platform that powers bit.bio discovery's ioCells™.
- Myllia Biotechnology: Vienna-based sister company (co-founded by Bürckstümmer in 2018) focused on single-cell CRISPR screens. As the other JV parent, it shares deep overlap in CRISPR functional genomics expertise and provides some technology and personnel overlap with bit.bio discovery.
- Editas Medicine: Clinical-stage CRISPR-based gene editing company developing therapeutic candidates; also historically developed CRISPR tools and screening capabilities. Comparable through its CRISPR platform expertise, though focused on therapeutics rather than discovery services.
Direct peers
- Synthego: Provider of CRISPR reagents, gene-edited iPSCs, and engineered cell models for research and therapeutic applications. Directly competes in the engineered iPSC and CRISPR tools space that bit.bio discovery serves.
- Cellecta: Offers functional genomics products and services including pooled CRISPR screening, shRNA libraries, and cell-based assay services. Closely comparable as a specialist provider of CRISPR screening services to pharma and biotech.
Regional players
- Fate Therapeutics: US-based iPSC-derived cell therapy company using engineered iPSC platforms for immuno-oncology. Adjacent in iPSC technology but differentiated as a therapeutic developer rather than a discovery services provider.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
bit.bio discovery social profiles
Digital presencebit.bio discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
bit.bio discovery leadership team
Management profileNumber of profiles
Profiles4 records
bit.bio discovery funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
bit.bio discovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about bit.bio discovery
What does bit.bio discovery do?
bit.bio discovery provides iPSC-derived cell models (ioWild Type Cells and ioDisease Model Cells) and custom cell engineering services for drug discovery research. The company runs CRISPR functional genomics screening services, including knockout, activation, and interference screens, on customer-supplied or proprietary iPSC-derived cells to support target identification, validation, pathway analysis, and disease modelling for pharmaceutical and biotechnology clients.
Is bit.bio discovery a public or private company?
bit.bio discovery is a private company. It is classified as corporate owned and is currently operating.
When was bit.bio discovery founded?
bit.bio discovery was founded in 2020. It employs 11 to 50 people.
Where is bit.bio discovery based?
bit.bio discovery is headquartered in Vienna, Austria, in the Europe region.
How does bit.bio discovery make money?
One revenue line is on record: CRISPR Screening Services.
Who are bit.bio discovery's main competitors?
Broad incumbents on record are Horizon Discovery (Revvity), Evotec, Charles River Laboratories and New England Biolabs. Emerging players are bit.bio, Myllia Biotechnology and Editas Medicine. Direct peers are Synthego and Cellecta. Fate Therapeutics is listed as a regional player.
Does bit.bio discovery have an API?
No public API is recorded for bit.bio discovery.
What industry is bit.bio discovery in?
bit.bio discovery's product category is Functional Genomics Screening Services. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.